" class="no-js "lang="en-US"> Steven Powell - Medtech Alert
Monday, August 04, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Steven Powell

Steven Powell

About Steven Powell

Steven has acquired broad experience in several life-science sectors in R&D, corporate finance and commercial roles. He started his career with Beecham Pharmaceuticals (now GSK) and subsequently held senior roles with both public and private biotechnology and healthcare companies in Europe and North America. He was also a partner with a European venture capital fund.

Related Story

Diseases

 eTheRNA Immunotherapies Opens Office in Hong Kong to Support and Build on its Growing Activities in China and Broader Asia-Pacific | Pharmtech Focus

eTheRNA Immunotherapies Opens Office in Hong Kong to Support and Build on its Growing Activities in China and Broader Asia-Pacific

August 3 2021

eTheRNA immunotherapies NV (‘eTheRNA’ or the ‘Company’), a clinical-stage company developing mRNA-based immunotherapies for the […]

Clinical Trials

 eTheRNA and VUB Expand Strategic Collaboration to Engineer Next Generation mRNA Therapeutics with TetraMix ® | Pharmtech Focus

eTheRNA and VUB to Engineer Next Generation mRNA Therapeutics with TetraMix ®

June 23 2021

eTheRNA immunotherapies NV (‘eTheRNA’, Niel, Belgium), a clinical-stage company developing mRNA-based immunotherapies for the treatment of […]